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Abstract
Purpose The aim of the study was to evaluate 18F-FDG-
PET/CT for the detection of synchronous primaries at initial
staging of patients with head and neck squamous cell
carcinoma (HNSCC).
Methods FDG-PET/CT images acquired between March
2001 and October 2007 in 589 consecutive patients (147
women, 442 men; mean age 61.5 years, age range 32–
97 years) with proven HNSCC were reviewed for the
presence of synchronous primaries. Cytology, histology
and/or clinical and imaging follow-up served as reference
standard.
Results FDG-PET/CT showed 69 suspected synchronous
primaries in 62 patients of which 56 were finally confirmed
in 44 patients. Of the 56 second cancers, 46 (82%) were
found in the aerodigestive tract in the following locations:
lung (26, 46%), head and neck (15, 17%), oesophagus (5,
9%). Ten second cancers (18%) were located outside the
aerodigestive tract (colon, five; stomach, lymphoma, breast,
thymus and kidney, one each). Six patients had three
synchronous primaries and three patients had four synchro-
nous cancers. Nine synchronous cancers were not detected
by PET/CT (four head and neck, two lung, two oesopha-
geal, one gastric). False-positive PET/CT findings were
mainly related to benign FDG uptake in the intestine due to
benign or precancerous polyps or physiological FDG
uptake in other head and neck regions. Overall the
prevalence of synchronous second primaries according to
the reference standard was 9.5%, of which 84% were
detected with FDG-PET/CT. In 80% of the patients, therapy
was changed because of the detection of a synchronous
primary.
Conclusion FDG-PET/CT detects a considerable number of
synchronous primaries (8.0% prevalence) at initial staging
of patients with HNSCC. Synchronous cancers were
predominantly located in the aerodigestive tract, primarily
in the lung, head and neck and oesophagus. Detection of
second primaries has an important impact on therapy. PET/
CT should be performed before panendoscopy.
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Introduction
Due to alcohol and nicotine abuse which is often
encountered in patients with head and neck squamous cell
carcinoma (HNSCC), they have an elevated risk of
developing synchronous and metachronous SCC in other
regions of the upper aerodigestive tract. Second cancers
predominantly affect the head and neck area, oesophagus or
the lung [1, 2]. The prevalence of a second SCC in cadaver
dissection studies ranges between 3.7% and 15.5% [3, 4].
For the highest-risk subgroups metachronous SCC occur in
about 4% of patients per year [5]. Panendoscopy studies
have shown the prevalence of synchronous primary SCC to
range from 1.4 to 17% [6]. At our institution a prevalence
of second primary tumours detected with panendoscopy of
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16.2% has been found, with 6.4% being synchronous and
9.8% being metachronous [6]. 18F-Fluoro-deoxy-glucose
positron emission tomography (FDG-PET/CT) is increas-
ingly used for staging of HNSCC with a considerable
impact on treatment decisions [7–9]. In comparison to
morphological imaging methods such as CT or MRI, PET/
CT has the great advantage of assessing the primary
tumour, the neck nodes and the potential distant metastases
and second primaries in a single examination. Detection
and staging of second primaries is of great importance
because it has a significant impact on treatment. Second
primaries are one reason for the lack of improvement in the
overall survival of these patients.
The aim of this study was to evaluate 18F-FDG-PET/CT
for the detection of synchronous primaries at the initial
staging of patients with HNSCC.
Materials and methods
Patients
From the first installation of a combined PET/CT scanner at
our institution in March 2001 until October 2007, 620
patients with biopsy-proven HNSCC were investigated with
18F-FDG-PET/CT for initial staging. Of these patients, 31
were excluded because they were lost to follow-up, or
adequate reports were not available. Therefore, the study
cohort consisted of 589 patients (147 men, 442 men; mean
age 61.5 years, age range 32–97 years). The indication for
PET/CT was mainly to rule out distant metastases in
patients with advanced HNSCC (large primary tumour
and/or clinical suspicion of lymph node metastases) prior to
therapy. The study was conducted in accordance with the
local guidelines established by the ethics committee for
retrospective evaluations. The patient characteristics are
summarized in Table 1.
FDG-PET/CT imaging
All the data were acquired on a combined PET/CT in-line
system (Discovery LS, Discovery STE, Discovery Rx; GE
Health Systems, Milwaukee, WI). These dedicated systems
integrate a PET scanner (GE Advance Nxi; GE Health
Systems) with a multislice helical CT (LightSpeed plus or
LightSpeed 16, LightSpeed VCT; GE Health Systems) and
permit the acquisition of coregistered CT and PET images
in one session.
Patients fasted for at least 4 h prior to scanning, which
started approximately 60 min after injection of a standard
dose of approximately 350 MBq of 18F-FDG. Oral CT
contrast agent (Micropaque Scanner, Guerbet, Aulnay-sous-
bois, France, or Gastrografin, Bayer-Schering, Berlin,
Germany) was given 15 min before injection of 18F-FDG.
Patients were examined in the supine position. Initially, the
CT scan was acquired starting from the level of the head
using the following parameters: 80 mA, 140 kV, 0.5 s per
tube rotation, slice thickness 4.25 mm, scan length 867 mm,
data acquisition time 12.5–22.5 s. The CT scan was
acquired during breath holding in the normal expiratory
position.
Immediately following the CT scan, a PET emission scan
was acquired with an acquisition time of 3 min per cradle
position with a one-slice overlap. The eight to nine cradle
positions from the knees to the head resulted in an
acquisition time of approximately 24–27 min. The CT data
were used for the attenuation correction and the images
were reconstructed using a standard iterative algorithm. The
acquired images were viewed with software providing
multiplanar reformatted images of PET alone, CT alone
and fused PET/CT with linked cursors using an Advantage
windows workstation (GE Health Systems). Additionally,
in 160 patients intravenous contrast agent was given and a
diagnostic neck CT scan from the base of the skull to the
aortic arch was performed after the PET scan.
PET/CT interpretation
The PET/CT images were retrospectively reviewed by a
doubly board-certified radiologist and nuclear medicine
physician with 10 years experience in CT reading and
Table 1 Characteristics of 589 patients with NNSCC
Women 147 (25.0%)
Men 442 (75.0%)
Age (years)
Mean 61.5
Range 32–97
Location of primary HNSCC
Nasopharynx 29 (4.9%)
Oral cavity 226 (38.4%)
Oropharynx 149 (25.3%)
Hypopharynx 89 (15.1%)
Larynx 61 (10.4%)
Unknown primary 27 (4.6%)
Other 8 (1.4%)
Stage of primary NNSCC
T-stage Tx 27 (4.6%)
T1 85 (14.4%)
T2 219 (37.2%)
T3 96 (16.3%)
T4 162 (27.5%)
N-stage N0 137 (23.3%)
N1 84 (14.3%)
N2 338 (57.4%)
N3 30 (5.1%)
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4 years experience in reading combined PET/CT in patients
with head and neck cancer for the presence of synchronous
primary tumours. The reader was blinded regarding the
results of clinical investigations including panendoscopy,
and other imaging including CT or MRI.
The PET images were analysed for the presence and
nature of focal lesions with increased FDG uptake. For all
patients, the attenuation-corrected PET images were used
for analysis. Lesions were interpreted as second tumours if
the uptake was higher than the uptake of the surrounding
background tissue so that a lesion was clearly detectable.
The morphology of suspicious lesions provided by the low-
dose CT part was also used for interpretation: for example,
in a spiculated solitary FDG-positive mass in the lung, a
second lung primary was diagnosed; in multiple non-
spiculated well-demarcated solid nodules in the lung,
metastases were diagnosed. FDG uptake typical of physi-
ological or benign variants such as in muscle, brown fat or
pulmonary infiltration, were not interpreted as second
primaries or distant metastases [10].
Reference standard
In patients with a suspected second primary, additional
investigations were performed. In the majority of patients
(420) additional panendoscopy was available as the
standard of reference. Patients with a suspected lung cancer
were referred to pulmonology for flexible bronchoscopy
with biopsy. Patients with a suspected oesophageal or colon
cancer were referred to gastroenterology for flexible
endoscopy with biopsy. In patients without a suspected
second primary, imaging (CT and/or PET/CT) and clinical
follow-up was performed for at least 6 months (mean
follow-up time 16.2 months, range 6–42 months).
Results
Overall, 56 synchronous tumours in 44 patients out of 589
evaluated patients were confirmed according to the above
mentioned reference standard. Thus, the prevalence of
synchronous primaries in our cohort according to the
standard of reference was 9.5%. Of these, synchronous
primaries, 47 (84%) were detected in 41 patients (93%) by
FDG-PET/CT.
Location of second primaries
Of the 56 second primary tumours, 46 (82%) were found in
the aerodigestive tract in the following locations: lung (26,
46%), upper aerodigestive tract (15, 27%), and oesophagus
(5, 9%). Ten second primary tumours (18%) were located
outside the aerodigestive tract (five colorectal, one stomach,
one lymphoma, one breast, one thymus, one kidney). The
locations of the synchronous second primary tumours are
summarized in Table 2. Thirty-five patients had one second
primary (Table 3). Six patients suffered from three
synchronous primary tumours (Table 4; Figs. 1 and 2) and
three patients had four synchronous primary tumours
(Table 5).
Extension and histology of the second primaries
Of the 56 synchronous primaries found, 25 (45%) were in
advanced stages (>T2 and/or N+ and/or M1), and 31 (55%)
were detected in a confined stage (T1/2, N0, M0). In the
majority of the second primaries detected a curative
treatment approach was possible. Only two patients already
showed distant metastases: one patient with an advanced
oral cavity SCC and a synchronous advanced non-small-
cell lung cancer had liver and bone metastases; and one
patient with a tonsillar SCC was diagnosed with an
advanced synchronous oesophageal cancer with distant
lymph node metastases. Furthermore, a stage IV synchro-
nous follicular lymphoma was detected, which required no
treatment. Another synchronous small-cell lung cancer was
detected with extended disease and was treated with
chemotherapy. Of the 56 synchronous malignancies, 38
(68%) were SCCs, and 15 (27%) were adenocarcinomas.
The majority of lung cancers were SCCs (77%), and the
majority of oesophageal cancers were also SCCs (60%). All
synchronous cancers in the colorectal area were adenocar-
cinomas. All synchronous cancers in the head and neck
region were SCCs.
Second cancers not detected by PET/CT
Nine synchronous cancers were detected by endoscopy and
not detected by PET/CT. Among the false-negative PET
findings were four small (T1) SCCs in the head and neck
area (one oral cavity, two oropharynx, one hypopharynx),
Table 2 Location of 56 confirmed second primaries
Location Number of tumours
Aerodigestive tract 46
Upper 15
Lower Oesophagus 5
Lung 26
Non-aerodigestive tract 10
Stomach 1
Colorectal 5
Thymus 1
Breast 1
Kidney 1
Lymphoma 1
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Table 3 Details of 35 patients with two synchronous primaries
Patient
no.
First tumour Therapy of first tumour Second tumour Additional therapy on detection of second tumour(s)
1 Larynx Curative radiotherapy NSCLC
(adenocarcinoma)
No (progressive lung cancer, not operable)
2 Oropharynx Palliative radiotherapy Stomach
(adenocarcinoma)a
No (died during radiation therapy)
3 Oral cavity Resection NSCLC (SCC) Chemotherapy
4 Oral cavity Curative radiotherapy NSCLC (SCC) Lobe resection
5 Oropharynx Curative radiochemotherapy NSCLC (SCC) Lobe resection
6 Oral cavity Curative radiochemotherapy Oropharynx (SCC) Extended radiotherapy field
7 Oral cavity Palliative chemotherapy NSCLC (SCC) No
8 Oral cavity Curative radiochemotherapy NSCLC
(adenocarcinoma)
Resection and mediastinal lymphadenectomy
9 Oral cavity Chemotherapy NSCLC
(adenocarcinoma)
Palliative chemotherapy instead of curative
dresection of oral cavity SCC
10 Oral cavity Resection Hypopharynx (SCC) Radiochemotherapy hypopharynx
11 Hypopharynx Curative radiochemotherapy Oesophagus (SCC) Curative radiochemotherapy oesophagus
12 Hypopharynx Palliative chemotherapy Rectum
(adenocarcinoma)
No
13 Larynx Curative radiochemotherapy NSCLC
(adenocarcinoma)
Lobe resection
14 Oral cavity Resection Oral cavity (SCC) Curative radiochemotherapy
15 Oral cavity Curative radiochemotherapy Follicular lymphoma No
16 Oral cavity Resection and neck dissection NSCLC (SCC) Palliative radiotherapy of thoracic wall
17 Oral cavity Resection NSCLC (SCC) Unknown
18 Oral cavity Resection Oral cavity (SCC) Curative radiochemotherapy
19 Oropharynx Chemotherapy, radiotherapy NSCLC (SCC) Radiotherapy of the NSCLC, chemotherapy
20 Oral cavity Resection Breast
(adenocarcinoma)
Ablation and lymph node dissection, adjuvant
chemotherapy
21 Oropharynx Curative radiotherapy NSCLC (SCC) No
22 Hypopharynx Curative radiotherapy NSCLC (SCC) No
23 Oropharynx Curative radiotherapy NSCLC (SCC) Unknown
24 Hypopharynx Curative radiochemotherapy Oral cavity (SCC) Resection
25 Oral cavity Resection and adjuvant
radiotherapy
NSCLC
(adenocarcinoma)
Lobe resection
26 Oral cavity Curative radiochemotherapy Rectum
(adenocarcinoma)
Resection
27 Oral cavity Unknown Rectum
(adenocarcinoma)
Unknown
28 Hypopharynx Palliative chemotherapy SCLC Chemotherapy of SCLC
29 Oropharynx Curative radiochemotherapy NSCLC (SCC) Resection
30 Oral cavity Curative radiotherapy NSCLC (SCC) Lost to follow-up
31 Larynx Resection NSCLC (SCC) Resection
32 Larynx Resection, neck dissection,
radiochemotherapy
NSCLC (SCC) Lobe resection, mediastinal lymphadenectomy,
radiotherapy of the mediastinum
33 Oral cavity Radiotherapy Oesophagus
(adenocarcinoma)a
Radiotherapy oesophagus
34 Oral cavity Resection, neck dissection
radiochemotherapy
NSCLC
(adenocarcinoma)
Resection and mediastinal lymph nodes
35 Cancer of
unknown
primary
Tonsillectomy,
radioimmunotherapy
Kidney (clear cell
carcinoma)
Nephrectomy
NSCLC non-small-cell lung cancer, SCC squamous cell cancer, SCLC small-cell lung cancer.
aMissed by PET.
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which were incidentally seen during panendoscopy. There
were two small adenocarcinomas of the oesophagus (T1N0
and T2N0), which were detected by panendoscopy and not
detected by PET/CT. One signet ring cell cancer of the
stomach, which showed no FDG uptake (T2N0) was
incidentally detected by endoscopy during placement of
the feeding tube. Additionally, two small bronchogenic
SCCs (both T1N0) were not visible on PET/CT but
detected by panendoscopy.
Reasons for false-positive PET/CT findings
False-positive PET/CT findings (22) were mainly related to
FDG uptake in the intestine due to benign or precancerous
Table 4 Details of six patients with three synchronous primaries
Patient
no.
First
tumour
Therapy of first tumour Second tumour Third tumour Additional therapy on detection
of second and third tumours
36 Oral cavity Resection Hypopharynx
(SCC)
NSCLC (SCC) Radiotherapy hypopharynx and thorax
37 Oral cavity Rfesection, neck dissection,
radiochemotherapy
Hypopharynx
(SCC)
Oesophagus (SCC) Radiochemotherapy hypopharynx, and
oesophagus
38 Oropharynx Curative radiotherapy Rectal cancer
(adenocarcinoma)
Thymus cancer
(SCC)
Resection of rectal and thymus cancer
39 Oral cavity Palliative NSCLC (SCC) Oesophagus
(adenocarcinoma)a
No
40 Oropharynx Resection NSCLC (SCC)a NSCLC (SCC)a Bilateral lung lobe resection and
mediastinal lymph node resection
41 Oropharynx No therapy Oesophagus (SCC) NSCLC (SCC) No
NSCLC non-small-cell lung cancer, SCC squamous cell cancer.
aMissed by PET.
Fig. 1 A 67-year old male
patient with proven oropharyn-
geal cancer. FDG-PET/CT
images showing the advanced
primary tumour (a, b long ar-
row) with multiple ipsilateral
lymph node metastases (a
arrowheads). Focal FDG-posi-
tive lesion (a, c short arrow) in
the anterior mediastinum, con-
firmed as thymus cancer on
histology. FDG-positive lesion
(a, d wide arrow) in the rectum
confirmed as rectal cancer on
histology
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polyps (eight), which can lead to focal FDG uptake mimicking
a small colon cancer. Another reason was physiological FDG
uptake in the head and neck area (five). The lymphoid tissue of
the tonsils and the musculature of the tongue especially can
show asymmetric FDG uptakemimicking small cancers. Other
reasons for nonmalignant FDG uptake were physiological
uptake in the intestine (two), inflammatory lesion in the lung
(four), rectum (one) and oesophagus (one), and FDG uptake in
a benign thyroid nodule (one).
Therapeutic changes due to detection of a second primary
In 32 of 40 patients (80%) with available follow-up,
the therapy was changed because of the detection of a
synchronous primary. Of these 32 patients, 15 received
additional surgery, 6 additional radiotherapy, 5 addi-
tional radiochemotherapy, and 6 additional chemother-
apy. Details of the changed therapies are shown in
Table 2.
Fig. 2 A 64-year old patient
with proven SCC of the right
tongue (a, b long arrow) with-
out lymph node metastases.
Additional detection of a FDG-
positive small mass in the piri-
form sinus on the left side (a, c
arrowhead), confirmed as syn-
chronous hypopharyngeal SCC.
FDG-positive tumour (a, d short
arrow) in the proximal oesoph-
agus, confirmed as another syn-
chronous SCC
Table 5 Details of three patients with four synchronous primaries
Patient
no.
First tumour Therapy of
first tumour
Second
tumour
Third tumour Fourth tumour Additional therapy caused by
the detection 2..3. and 4. tumours
42 Hypopharynx Curative
radiochemotherapy
Oral cavity
(SCC)
Oropharynx
(SCC)
Rectal cancer
(adenocarcinoma)
Radiochemotherapy for oral cavity
and oropharynx cancers,
neoadjuvant radiotherapy,
mesorectal resection, adjuvant
chemotherapy
43 Hypopharynx Curative
radiotherapy
Oral cavity
(SCC)a
Hypopharynx
(SCC)a
Hypopharynx
(SCC)
More extended radiotherapy
44 Oral cavity Resection Hypopharynx
(SCC)
Oropharynx,
right side
(SCC)a
Oropharynx, left
side (SCC)a
Resection
SCC squamous cell cancer.
aMissed by PET.
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Discussion
Our study in a large cohort of patients with HNSCC
showed that a high number of synchronous cancers can be
detected by FDG-PET/CT at initial staging. There are only
a few studies concerned with the detection of second
primaries with FDG-PET or FDG-PET/CT. Fleming et al.
described 123 patients with head and neck tumours initially
staged with FDG-PET/CT [7]. PET/CT indicated ten
suspected synchronous primaries (8.1%). In three of these
patients the finding was false-positive caused by inflam-
mation, in one patient a false-negative result turned out to
be a papillary thyroid carcinoma, and in six patients the
suspicious findings were confirmed (one NSCLC, one
lymphoma, one breast cancer, one thyroid cancer, one
oesophageal cancer, and one prostate cancer). Thus,
regarding their reference standard, the prevalence of second
cancers in their population was 4.9%, which is lower than
in our study with a similar positive predictive value of 60%.
Interestingly, only two of the detected second primaries
were located in the aerodigestive tract (33.3%), compared
with 82% in our population. The studies are difficult to
compare, because the patient population in the study by
Fleming et al. was much more inhomogeneous than ours:
Fleming et al. included about 25% patients without SCC
histology [7].
Schwartz et al. staged 33 HNSCC patients with FDG-
PET and found three synchronous cancers (one lung cancer,
one oesophageal cancer and one colon cancer), leading to a
prevalence of second cancers of 9.1% [11]. Schmid et al.
performed FDG-PET/CT in 84 patients with HNSCC and
found two lesions suspected to be second cancers, one a
lung cancer and one a polyp in the colon, leading to a low
prevalence of 1.2% of second primaries [12]. In another
study by the same group, four second primaries (two lung,
one prostate, two colon) were detected in 34 patients with
oral cavity cancer, resulting in an prevalence of synchro-
nous primaries of 12% [13].
The majority of second primaries in our study were
located in the lung, and the predominant histology was
SCC. Wax et al. compared FDG-PET imaging with chest
radiography and chest CT scans in 59 untreated patients
with HNSCC with regard to the presence of synchronous
lung lesions. They found 15 patients with suspicious lung
lesions, of which ten were further investigated. Two
findings turned out to be false-positive, whereas in eight
patients, a second primary was confirmed (one small-cell
lung cancer, seven NSCLC). Staging using FDG-PET was
superior to other imaging modalities and significantly
superior to bronchoscopy for the detection of second
primaries located in the lung as well as lung metastases
[14–16]. Atabek et al. described a total prevalence of 5.4%
lung cancers in patients with HNSCC [17]. Regarding lung
metastases it has been shown in a prospective multicentre
trial in patients with HNSCC with risk factors that
pretreatment screening for distant metastases by chest CT
is improved by FDG-PET [18].
The second most encountered synchronous primaries in
our study were SCCs located in the head and neck region.
The pathogenesis of multiple SCCs in the digestive tract
has been well explained by Slaughter et al. with their theory
of field cancerization [19].
As expected we found several focal FDG accumulations in
the colon (3%). Incidentally detected focal lesions in the colon
should be clarified with endoscopy, and our results confirm
this recommendation because invasive cancers were found in
five patients and precancerous polyps in another eight
patients. These findings are in line with the findings of Kamel
et al. who evaluated a large number of PET/CT studies (3,281
patients) and found focal intestinal FDG uptake in 3% (19%
malignant, 42% precancerous, 17% inflammatory, 8% benign
tumours, 13% “physiologic”) [20].
In a previous panendoscopy study at our institution most
of the synchronous second primaries were found in the
upper aerodigestive tract (60%) [6]. In the present study, the
minority (27%) of the aerodigestive tract cancers were in
the upper part. This is explained by the fact that many lung
cancers and some oesophageal cancers might be missed by
endoscopy due to their peripheral localization or submuco-
sal growth, highlighting the additional impact of FDG-PET/
CT in patients who have already undergone panendoscopy.
Although FDG-PET/CT is a very accurate imaging modal-
ity, the study shows the drawbacks of FDG-PET/CT. Due to
the limited spatial resolution, small and superficially
growing tumours in the aerodigestive tract can be invisible.
Thus FDG-PET/CT will not replace endoscopy in this
patient group and these techniques are complementary.
There are a variety of malignant tumours which might be
FDG-negative and consequently missed by FDG-PET/CT,
such as bronchoalveolar carcinomas, neuroendocrine
tumours, low-grade sarcomas or signet ring cell adenocar-
cinomas [21–23]. In our experience the CT part of the PET/
CT study can partially help to overcome this limitation by
showing suspicious morphological changes.
Furthermore, FDG-PET/CT produces a considerable
number of false-positive results, especially in regions were
physiological FDG uptake is observed frequently, such as
in the upper aerodigestive region and the intestine. These
findings might cause additional diagnostic, often invasive
and costly procedures, as well as further anxiety to the
patient [10]. In the head and neck area the false-positive
findings can be easily checked by office examination or
endoscopy in most patients. We observed a learning curve
in reading FDG-PET/CT scans and false-positives can be
avoided with increasing experience of the PET/CT reader.
Generally, faint symmetric FDG uptake more likely
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represents a benign lesion whereas asymmetric high uptake
often represents a malignant tumour. Compared to the
original reports, our experienced reader were able to reduce
the number of false-positives from 25 to 22. The resection
of precancerous lesions in the colon, counted as false-
positives in this study, is reasonable and helps to prevent
the patient from developing a malignant lesion in the colon.
Our results show that the majority of the second tumours
were detected in an early stage where curative treatment is still
an option. The lung cancers especially were curable in many
patients. In 80% of the patients, the detection of a second
primary had an impact on therapy, as resection of the second
primary was performed in the majority of patients.
It is still a matter of controversy as to how FDG-PET/CT
should be integrated into the staging algorithm of patients
with HNSCC [24]. We use FDG-PET/CT in patients with
suspected advanced primaries and/or metastases, and we
recommend that it should be performed prior to panendo-
scopy. FDG-PET/CT seems to be an ideal tool to guide
biopsy to the metabolically active lesions, and consequently
panendoscopy performs better with the knowledge of the
PET results. Furthermore, biopsies might cause false-
positive FDG uptake due to inflammation, which can be
troublesome for the PET/CT reader. The false-negative
findings in this study by panendoscopy were all peripheral
lung malignancies, where panendoscopy cannot be used
appropriately, or lesions with slow submucosal growth and
therefore hardly detectable. Therefore, the combination of
FDG-PET/CT and PET/CT-guided endoscopy might be the
most sensitive approach to detecting synchronous tumours
in an early treatable stage. Whether this approach improves
the outcome in terms of overall survival and its cost-
effectiveness have to be evaluated in the future.
Our study had limitations. We could not compare the FDG-
PET/CT findings with panendoscopy in every patient. Due to
the installation of a new scanner during the study, the imaging
technique was not exactly the same for all patients. Addition-
ally, our head and neck cancer PET/CT protocol changed
during the study. A contrast-enhanced neck CT scan was
implemented, and this might have increased the accuracy but
should not have had too much influence on the detection and
characterization of second primaries. Due to the retrospective
design we cannot reliably say how many of the detected
cancers were already known or suspected clinically before
PET/CT imaging. We want to point out that if a lung cancer is
known already from panendoscopy a FDG-PET/CT scan is
still useful and regularly performed in our institution for
staging and treatment guidance.
Conclusion
In conclusion, FDG-PET/CT detects a considerable number
of synchronous primaries (8.0% prevalence) at initial
staging of patients with HNSCC. Synchronous cancers
were predominantly located in the aerodigestive tract,
primarily in the lung, head and neck, and oesophagus.
The detection of synchronous primaries has an important
therapeutic impact. PET/CT should be performed before
panendoscopy.
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